SNDX — Syndax Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$20.10
+$0.81 (+4.20%)
Syndax Pharmaceuticals Inc (SNDX) is a biotechnology company listed on NASDAQ. It is led by Michael A. Metzger M.B.A., based in 730 Third Avenue, New York, NY, United States, 10017, with about 270 employees. Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Latest reported SNDX revenue for 2025-09-30 was $45.9M. Net income was -$217.4M. Revenue was up 20.8% from 2025-06-30 to 2025-09-30. SNDX currently screens at market cap $774.4M.
Use this SNDX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SNDX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SNDX SEC filings page. Lician reads the product cache first so this HTML stays unique to Syndax Pharmaceuticals Inc even when a live quote feed is slow.
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
SNDX Key Statistics
Market Cap
$774.43M
Volume
973,595
Previous Close
$19.57
Day Range
$19.70 – $20.40
EPS
-$3.72
Revenue
$23.68M
Net Income
-$318.76M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-1346.1%
Employees
270
SNDX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $23.68M | $0.00 | $0.00 | $139.71M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$318.76M | -$209.36M | -$149.34M | $24.93M |
| EPS (Diluted) | -$3.72 | -$2.98 | -$2.46 | $0.46 |
Total Assets
$724.82M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$154.08M
Operating Cash Flow
-$274.90M
Free Cash Flow
$0.00
Syndax Pharmaceuticals Inc Company Information
- CEO & Director
- Michael A. Metzger M.B.A.
- Headquarters
- 730 Third Avenue, New York, NY, United States, 10017
- Website
- syndax.com
- Phone
- 781 419 1400
- IPO / Founded
- 2016-03-03
- Sector
- Healthcare
- Industry
- Biotechnology